drugset / Trial / NCT04935112

A Study to Explore the Effect of Acid-reducing Agents

NCT04935112

Phase 1 Completed 15 enrolled Mirati Therapeutics Inc.
Non-randomizedCrossoverOpen-labelOther

Summary

A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center, open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.

Timeline

Start
2021-07-07
Primary completion
2021-08-12
Completion
2022-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 40 mg Oral
Subject Pantoprazole Other / unclassified 40 mg Oral
Subject Sitravatinib Small molecule 100 mg Oral

Indications

No indication recorded.